Drug Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer and Coping Strategy: Discussion based on Yang Deficiency
10.13288/j.11-2166/r.2017.17.008
- VernacularTitle:从阳气亏虚探讨非小细胞肺癌表皮生长因子受体-酪氨酸激酶抑制剂耐药及应对策略
- Author:
Lei LIU
;
Zhenxiang LI
;
Jun XIAO
;
Jiamao LIN
- Keywords:
non-small cell lung cancer;
epidermal growth factor receptor tyrosine kinase inhibitor;
drug resistance;
Yang deficiency
- From:
Journal of Traditional Chinese Medicine
2017;58(17):1466-1468,1490
- CountryChina
- Language:Chinese
-
Abstract:
Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) is a kind of targeted drug for the treatment of non-small cell lung cancer (NSCLC),but almost all patients develop EGFR-TKI resistance.In Chinese medicine,it is believed that Yang deficiency is the leading cause of tumor,which could end up with the internal formation of cancer toxin and promote the formation of tangible excess pathogens.Clinical and experimental studies have shown that the Chinese medicine treatment based on Yang-warming method can inhibit EGFR-TKI resistance and improve the therapeutic effect of EGFR-TKI.The mechanism may be related to the regulation of miRNA gene and estrogen receptor expression,being against tumor heterogeneity and the regulation of tumor microenvironment.Therefore,Yang deficiency is the key pathogenesis of the EGFR-TKI resistance in NSCLC,and the method reinforcing Yang and suppressing Yin is the basic therapeutic way in Chinese medicine to overcome EGFR-TKI resistance.
